1. Alirocumab reduces total coronary plaque burden in patients with familial hypercholesterolaemia and no previous clinical atherosclerotic disease. (3rd October 2022) Authors: Perez De Isla, L; Diaz Diaz, J L; Romero, M J; Muniz Grijalvo, O; Argueso, R; Sanchez Munoz Torrero, J F; Mediavilla, J D; Ponte, P; Fuentes, F; Saltijeral Cerezo, A; Alvarez Banos, P; Rubio, P; Cepeda, J M; Padro, T; Mata, P Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Persistence to long-term PCSK9 inhibitors treatment and its effectiveness in familial hypercholesterolemia: data from the SAFEHEART study. (3rd October 2022) Authors: Alonso, R; Arroyo-Olivares, R; Muniz-Grijalvo, O; Diaz-Diaz, J L; Sanchez Munoz-Torrero, J; Zambon, D; Fuentes-Jimenez, F; Romero, M J; Aguado, R; Alvarez-Banos, P; Manas, M D; Arrieta, F; Gonzalez-Bustos, P; Argueso, R; Mata, P Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗